French Parasitology Alliance For Health Care


The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive scientific opinion of fexinidazole, the first all-oral treatment that has been shown to be Fexinidazole162018 1024x683
efficacious for both stages of sleeping sickness. This approval is a result of clinical trials led by the non-profit research and development organization DNDi and an application submitted by Sanofi. The decision paves the way for the distribution of fexinidazole in endemic countries in 2019.

 

More details :

https://www.ema.europa.eu/en/news/chmp-recommends-first-oral-only-treatment-sleeping-sickness

https://www.dndi.org/2018/media-centre/press-releases/ema-recommends-fexinidazole-first-all-oral-treatment-sleeping-sickness/